Nicotinamide cooperates with retinoic acid and 1,25-dihydroxyvitamin D 3 to regulate cell differentiation and cell cycle arrest of human myeloblastic leukemia cells

Oncology

Volumn 76, Issue 2, 2009, Pages 91-100

  Shen, Miaoqing ^a   Yen, Andrew ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

Arrest; Cell differentiation; Leukemia; Nicotinamide; Retinoic acid; Vitamin D3

Indexed keywords

CALCITRIOL; CD11B ANTIGEN; CD14 ANTIGEN; CD38 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RETINOIC ACID;

AEROBIC METABOLISM; ANTIGEN EXPRESSION; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL;

ANTIGENS, CD11B; ANTIGENS, CD14; ANTIGENS, CD38; CALCITRIOL; CELL CYCLE; CELL DIFFERENTIATION; DRUG SYNERGISM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOMONOCYTIC, ACUTE; NIACINAMIDE; TRETINOIN;

EID: 58149166321     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000188664     Document Type: Article

References (43)

1. Knip M, Douek IF, Moore WPT, Gillmor HA, McLean AE, Bingley PJ, Gale EA, European Nicotinamide Diabetes Intervention Trial Group: Safety of high-dose nicotinamide: a review. Diabetologia 2000;43:1337-1345.
2. Ogata S, Takeuchi M, Okumura K, Taguchi H: Apoptosis induced by niacin-related compounds in HL-60 cells. Biosci Biotechnol Biochem 1998;62:2351-2356.
3. Daniel J, Marechal Y, van Gool F, Andris F, Leo O: Nicotinamide inhibits B lymphocyte activation by disrupting MAPK signal transduction. Biochem Pharmacol 2007;73:831-842.
4. Szabo C: Cell Death: the Role of PARP. Boca Raton, CRC Press, 2000, vol 17, pp 439-440.
5. DeMurcia G, Shall S: From DNA Damage and Stress Signaling to Cell Death: Poly ADP-Ribosylation Reactions. Oxford, Oxford University Press, 2001, p 260.
6. Shiokawa D, Maruta H, Tanuma S: Inhibitors of poly(ADP-ribose) polymerase suppress nuclear fragmentation and apoptoticbody formation during apoptosis in HL-60 cell. FEBS Lett 1997;413:99-103.
7. Schreiber V, Dantzer F, Ame JC, de Murcia G: Poly(ADP-ribose): novel functions for an old molecular. Nat Rev Mol Cell Biol 2006;7:517-528.
8. Szabo C: PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News Perspect 2002;15:197-205.
9. Dulin WE, Wyse M: Reversal of streptozotocin diabetes with nicotinamide. Proc Soc Exp Biol Med 1969;130:992-994.
10. Su CF, Liu DD, Kao SJ, Chen HI: Nicotinamide abrogates acute lung injury caused by ischemia-reperfusion. Eur Respir J 2007;30:199-204.
11. Iwata K, Ogata S, Okumura K, Taguchi H: Induction of differentiation in human promyelocytic leukemia HL-60 cell line by niacin-related compounds. Biosci Biotechnol Biochem 2003;67:1132-1135.
12. Munshi CB, Graeff R, Lee HC: Evidence for a causal role of CD38 expression in granulocytic differentiation of human HL-60 cells. J Biol Chem 2002;277:49453-49458.
13. Merzvinskyte R, Treigyte G, Savickiene J, Maqnusson KE, Navakauskiene R: Effects of histone deacetylase inhibitors, sodium phenyl butyrate and vitamin B3, in combination with retinoic acid on granulocytic leukemia HL-60 cells. Ann NY Acad Sci 2006;1091:356-367.
14. Vaca P, Berna G, Martin F, Soria B: Nicotinamide induces both proliferation and differentiation of embryonic stem cells into insulin-producing cells. Transplant Proc 2003;35:2021-2023.
15. Yen A, Brown D, Fishbaugh J: Control of HL-60 monocytic differentiation. Different pathways and uncoupled expression of differentiation markers. Exp Cell Res 1987;168:247-254.
16. Yen A, Roberson MS, Varvayanis S, Lee AT: Retinoic acid induces mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 1998;58:3163-3172.
17. Lamkin TJ, Chin V, Varvayanis S, Smith JL, Sramkoski RM, Jacobberger JW, Yen A: Retinoic acid-induced CD38 expression in HL-60 myeloblastic leukemia cells regulates cell differentiation or viability depending on expression levels. J Cell Biochem 2006;97:1328-1338.
18. Zubiaur M, Fernandez O, Ferrero E, Salmeron J, Malissen B, Malavas F, Sancho J: CD38 is associated with lipid rafts and upon receptor stimulation leads to Akt/protein kinase B and Erk activation in the absence of the CD3-zeta immune receptor tyrosine-based activation motifs. J Biol Chem 2002;277:13-22.
19. Koeffler HP: Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implication. Blood 1983;62:709-721.
20. Vague P, Picq R, Bernal M, Lassmann-Vague V, Vialettes B: Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetic patients. Diabetologia 1989;32:316-321.
21. Ungerstedt JS, Blomback M, Soderstrom T: Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol 2003;131:48-52.
22. Brooks SC 3rd, Kazmer S, Levin AA, Yen A: Myeloid differentiation and RB phosphorylation changes in HL-60 cells induced by RAR- and RXR-selective retinoic acid analogs. Blood 1996;87:227-237.
23. Battle T, Yen A: Ectopic expression of CXCR5/BLR1 accelerates retinoic acid- and vitamin D(3)-induced monocytic differentiation of U937 cells. Exp Biol Med 2002;227:753-762.
24. Yen A, Placanica L, Bloom S, Varvayanisi S: Polyomavirus small t antigen prevents retinoic acid-induced retinoblastoma protein hypophosphorylation and redirects retinoic acid-induced G0 arrest and differentiation to apoptosis. J Virol 2001;75:5302-5314.
25. Daniel CP, Parreira A, Goldman JM, McCarthy DM: The effect of 1,25-dihydroxyvitamin D3 on the relationship between growth and differentiation in HL-60 cells. Leuk Res 1987;11:191-196.
26. Wang Q, Salman H, Danilenko M, Studzinski GP: Cooperation between antioxidants and 1,25-dihydroxyvitamin D3 in induction of leukemia HL-60 cell differentiation through the JNK/AP-1/Egr-1 pathway. J Cell Physiol 2005;204:964-974.
27. Wang J, Yen A: A MAPK positive feedback mechanism for Blr1 signaling propels retinoic acid triggered differentiation and cell cycle arrest. J Biol Chem 2008;283:4375-4386.
28. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ: Structure and function of lipopolysaccharide binding protein. Science 1990;249:1429-1431.
29. Pugin J, Ulevitch RJ, Tobias PS: Activation of endothelial cells by endotoxin: direct versus indirect pathways and the role of CD14. Prog Clin Biol Res 1994;392:369-373.
30. Jacobson MK, Jacobson EL: ADP-Ribose Transfer Reactions: Mechanisms and Biological Significance. New York, Springer, 1989.
31. Poirier G, Moreau P: ADP-Ribosylation Reactions. New York, Springer, 1992.
32. Pavri R, Lewis B, Kim TK, Dilworth FJ, Erdjument-Bromage H, Tempst P, de Murcia G, Evans R, Chambon P, Reinberq D: PARP-1 determines specificity in a retinoid signaling pathway via direct modulation of mediator. Mol Cell 2005;18:83-96.
33. Agote RM, Finochietto P, Gamba CA, Dagrosa MA, Viaqqi ME, Franco MC, Poderoso JJ, Juvenal GJ, Pisarev MA: Nicotinamide increases thyroid radiosensitivity by stimulating nitric oxide synthase expression and the generation of organic peroxides. Horm Metab Res 2006;38:12-15.
34. Cabrera-Rode E, Molina G, Arranz C, Vera M, Gonzalez P, Suarez R, Prieto M, Padron S, Leon R, Tillan J, Garcia I, Tiberti C, Rodriquez OM, Gutierrez A, Fernandez T, Govea A, Hernandez J, Chiong D, Dominquez E, Di Mario U, Diaz-Diaz O, Diaz-Horta O: Effect of standard nicotinamide in the prevention of type 1 diabetes in first degree relatives of persons with type 1 diabetes. Autoimmunity 2006;39:333-340.
35. Southan GJ, Szabo C: Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem 2003;10:321-340.
36. Deaglio S, Capobianco A, Bergui L, Dürig J, Morabito F, Dührsen U, Malavasi F: CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003;102:2146-2155.
37. Howard M, Grimaldi JC, Bazan JF, Lund FE, Santos-Argumedo L, Parkhouse RM, Walseth TF, Lee HC: Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science 1993;262:1056-1059.
38. Zocchi E, Franco L, Cuida L, Benatti U, Bargellesi A, Malavasi F, Lee HC, De Flora A: A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. Biochem Biophys Res Commun 1993;196:1459-1465.
39. Gallay N, Anani L, Lopez A, Colombat P, Binet C, Domenech J, Weksler BB, Malavasi F, Herault O: The role of platelet/endothelial cell adhesion molecule 1 (CD31) and CD38 antigens in marrow microenvironmental retention of acute myelogenous leukemia cells. Cancer Res 2007;67:8624-8632.
40. Ferrero E, Saccucci F, Malavasi F: The human CD38 gene: polymorphism, CpG island, and linkage to the CD157 (BST-1) gene. Immunogenetics 1999;49:597-604.
41. Deaglio S, Malavasi F: The CD38/CD157 mammalian gene family: an evolutionary paradigm for other leukocyte surface enzymes. Purinergic Signal 2006;2:431-441.
42. Malavasi F, Deaglio S, Ferrero E, Funaro A, Sancho J, Ausiello CM, Ortolan E, Vaisitti T, Zubiaur M, Fedele G, Aydin S, Tibaldi EV, Durelli I, Lusso R, Cozno F, Horenstein AL: CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity. Mol Med 2006;12:334-341.
43. Dong C, Willerford D, lt FW, Cooper MD: Genomic organization and chromosomal localization of the mouse Bp3 gene, a member of the CD38/ADP-ribosyl cyclase family. Immunogenetics 1996;45:35-43.